IPO - Theriva Biologics, Inc.

Form Type: S-1/A

Filing Date: 2025-03-21

Corporate Action: Ipo

Type: New

Accession Number: 000110465925026682

Filing Summary: Theriva Biologics, Inc. is conducting a public offering of up to 8,403,361 shares of common stock, alongside warrants, to finance its oncology-focused therapeutic developments. The prospectus outlines various aspects of the offering including estimated proceeds of approximately $8.95 million if all shares are sold at an assumed price of $1.19. The offering is structured as a best efforts basis and does not impose a minimum sale condition. Notably, the company is emerging from a strategic transformation, following an acquisition of VCN Biosciences in March 2022, shifting its focus to oncology and detailing its lead product candidate, VCN-01, which is currently in clinical trials for various cancers. Additionally, the document cites risks associated with the offering and investor participation without a guaranteed refund or minimum sale, which may impact the company's ability to fulfill business objectives.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-01-21

Corporate Action: Ipo

Type: New

Accession Number: 000110465925004895

Filing Summary: Theriva Biologics, Inc. is registering for an initial public offering (IPO) of up to 6,756,756 shares of common stock and associated warrants, adopting a strategic focus on oncology. The offer includes common warrants and pre-funded warrants allowing for the purchase of additional shares of common stock, with the total offering potentially reaching 13,513,512 shares underlying the various warrants. The assumed public offering price is $1.48 per share based on prior market activity on January 17, 2025. The company, which has transitioned from its initial focus on gastrointestinal diseases to oncology following the acquisition of VCN Biosciences in March 2022, is currently developing a lead product candidate (VCN-01) for treatment in clinical trials targeting pancreatic cancer and other solid tumors. A.G.P./Alliance Global Partners is the sole placement agent for this offering, which is aimed at raising funds to support the company’s strategic objectives and clinical trials, with closure expected by February 12, 2025. Risks associated with the offering include the potential for insufficient investor interest leading to reduced proceeds and challenges in selling the securities, emphasizing that there is no minimum offering requirement for closing.

Document Link: View Document